黄芩苷预治疗对小鼠红细胞输注模型中IgG和IgM抑制作用的研究*

doi:10.3969/j.issn.1671-2587.2024.05.005

临床输血与检验 ›› 2024, Vol. 26 ›› Issue (5): 604-608.DOI: 10.3969/j.issn.1671-2587.2024.05.005

黄芩苷预治疗对小鼠红细胞输注模型中IgG和IgM抑制作用的研究^*

蒋雪玉, 杨懿铭, 孙娟, 谢如锋, 高跞, 杨洁

上海市血液中心输血研究所,上海 200051

收稿日期:2024-06-06 出版日期:2024-10-20 发布日期:2024-09-20
通讯作者: 杨洁,主要从事细胞治疗、输血医学研究工作,（E-mail）yangjie@sbc.org.cn。
作者简介:蒋雪玉,主要从事输血医学科研工作,（E-mail）jiangxueyu@sbc.org.cn。
基金资助:
*本课题受上海市卫生健康委员会面上项目（No.201940111; 202140008）、上海市血液中心科技基金项目（No.103J2302-04）资助

Pretreatment with Baicalin Reduces the Production of IgG and IgM in a Mouse Model of Red Blood Cell Infusion

JIANG Xueyu, YANG Yiming, SUN Juan, XIE Rufeng, GAO Li, YANG Jie

Shanghai Blood Center Blood Transfusion Research Institute, Shanghai 200051

Received:2024-06-06 Online:2024-10-20 Published:2024-09-20

摘要/Abstract

摘要： 目的探讨采用黄芩苷预治疗对红细胞免疫的预防性效果。方法采用人类红细胞与佐剂脂多糖（LPS）联合输注C57BL/6小鼠建立红细胞输注模型。设立（1）红细胞输注模型组;（2）未处理对照组：仅注射PBS;（3）黄芩苷预治疗组：在红细胞输注模型建立前一周每天给予小鼠黄芩苷（250 mg/（kg·day））治疗;（4）地塞米松（DEX）对照组：在红细胞输注模型建立前一周每天给予地塞米松（5 mg/（kg·day））治疗。通过流式细胞术检测小鼠血清中IgG和IgM 的表达量,并监测小鼠脾脏中的CD4 T细胞和B细胞变化。结果与模型组相比,黄芩苷预治疗能显著降低血清IgG（24 823.0±1 452.2 vs 15 180.0±1 172.5,P<0.05）和IgM（194 206±2 868.6 vs 112 287±9 741.5,P<0.05）的生成。与模型组相比,黄芩苷预处理组小鼠脾脏中CD25表达明显下降（1 006.0±206.1 vs 548.4±19.1,P<0.05）,B细胞比例显著降低（31.16%±6.06% vs 15.69%±4.59%,P<0.05）,脾脏大小无显著差异[平均长度：（10±0.5）mm vs （12±0.5）mm,P>0.05]。结论黄芩苷能够抑制红细胞免疫,表现为抑制小鼠血清中IgG和IgM的生成,同时抑制脾脏中B细胞增殖和降低CD4 T细胞活化。

关键词: 黄芩苷, 红细胞免疫, 抗体生成

Abstract: Objective To investigate the prophylactic effects of pretreatment with baicalin on erythrocyte alloimmunization. Methods A model of red blood cell (RBC) infusion was established in C57BL/6 mice through co-infusion of human RBCs and lipopolysaccharide (LPS) as an adjuvant. Mice were randomly assigned into four experimental groups: (1) RBC infusion model group; (2) Untreated control group: injection of PBS only; (3) Baicalin pretreatment group: mice were given baicalin (250 mg/（kg·day）) daily for one week prior to the establishment of the RBC infusion model; (4) Dexamethasone (DEX) control group: DEX (5 mg/（kg·day）) were given daily for one week prior to the establishment of the RBC infusion model. The expression levels of IgG and IgM in the mice serum were analyzed by flow cytometry, and changes in CD4 T cells and B cells in the spleen were monitored. Results Compared to the RBC infusion model group, baicalin pretreatment significantly reduced the production of serum IgG (24 823.0±1 452.2 vs. 15 180.0±1 172.5, P<0.05) and IgM (194 206±2 868.6 vs. 112 287±9 741.5, P<0.05). Compared with the model group, there was a significant decrease in the expression of CD25 (1 006.0 ±206.1 vs. 548.4±19.1, P<0.05) and the proportion of B cells (31.16%±6.06% vs. 15.69%±4.59%, P<0.05) in the spleens of baicalin-pretreated mice, and no significant difference in the spleen size (mean length: 10±0.5 mm vs. 12±0.5 mm, P>0.05). Conclusion Baicalin effectively suppresses erythrocyte alloimmunization by inhibiting the production of IgG and IgM in the serum, as well as the inhibition of B cell proliferation and CD4 T cell activation in the spleen.

Key words: Baicalin, Erythrocyte alloimmunization, Antibody production

中图分类号:

R457

蒋雪玉, 杨懿铭, 孙娟, 谢如锋, 高跞, 杨洁. 黄芩苷预治疗对小鼠红细胞输注模型中IgG和IgM抑制作用的研究^*[J]. 临床输血与检验, 2024, 26(5): 604-608.

JIANG Xueyu, YANG Yiming, SUN Juan, XIE Rufeng, GAO Li, YANG Jie. Pretreatment with Baicalin Reduces the Production of IgG and IgM in a Mouse Model of Red Blood Cell Infusion[J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(5): 604-608.

参考文献

[1] 陈蕙英. 妊娠期服黄疸茵陈冲剂预防新生儿溶血症[J].新医药学杂志,1978,(11):19-21.
[2] 陈蕙英. 妊娠期服黄疸茵陈冲剂预防新生儿高胆红素血症[J].中医杂志,1982,(2):37-38.
[3] LIN C C,SHIEH D E.The anti-inflammatory activity of Scutellaria rivularis extracts and its active components, baicalin,baicalein and wogonin[J]. Am J Chin Med, 1996,24(1):31-36.
[4] ZHANG G X,ZHANG Y,LI X. Therapeutic efficacy of baicalin on experimental autoimmune encephalomyelitis through down-regulation of JAK-STAT and NF-κB signaling pathways (THER3P.876)[J]. J Immunol,2014, 192(1_Supplement):136.2.
[5] YANG J,YANG X,LI M.Baicalin,a natural compound, promotes regulatory T cell differentiation[J]. BMC Complement Altern Med,2012, 12:64.
[6] MA C H,MA Z Q,FU Q,et al.Anti-asthmatic effects of baicalin in a mouse model of allergic asthma[J]. Phytother Res,2014,28(2):231-237.
[7] HONG T,JIN G B,CHO S,et al.Evaluation of the anti-inflammatory effect of baicalein on dextran sulfate sodium-induced colitis in mice[J]. Planta Med,2002, 68(3):268-271.
[8] ZOU Y,DAI S X,CHI H G,et al.Baicalin attenuates TNBS-induced colitis in rats by modulating the Th17/Treg paradigm[J]. Arch Pharm Res,2015,38(10):1873-1887.
[9] XU L,LI J X,ZHANG Y,et al.Regulatory effect of baicalin on the imbalance of Th17/Treg responses in mice with allergic asthma[J]. J Ethnopharmacol, 2017, 208:199-206.
[10] 马印图,李莉华,李丽君,等. 茵栀黄口服液联合血浆置换早期干预治疗母婴血型不合新生儿溶血病[J]. 中国输血杂志,2013,26(10):993-996.
[11] YAZDANBAKHSH K,WARE R E,NOIZAT-PIRENNE F.Red blood cell alloimmunization in sickle cell disease: pathophysiology,risk factors,and transfusion management[J]. Blood,2012,120(3):528-537.
[12] SHIEH S J,VARKEY P,CHEN P Y,et al.Counting CD4+ and CD8+ T cells in the spleen:a novel in vivo method for assessing biomaterial immunotoxicity[J]. Regen Biomater, 2014,1(1):11-16.
[13] NATIONAL Research Council Subcommittee on Immunotoxicology. Biologic markers in immunotoxicology[J]. 1992.
[14] WANG L,HUANG S Y,LIANG X L,et al.Immuno-modulatory role of baicalin in atherosclerosis prevention and treatment:current scenario and future directions[J]. Front Immunol,2024,15:1377470.
[15] WAN L N,LI Y C,LIAO W H,et al.Synergistic inhibition effects of andrographolide and baicalin on coronavirus mechanisms by downregulation of ACE2 protein level[J]. Sci Rep,2024,14(1):4287.
[16] TOSATO G,SEAMON K B,GOLDMAN N D, et al.Monocyte-derived human B-cell growth factor identified as interferon-beta 2 (BSF-2,IL-6)[J]. Science, 1988,239(4839):502-504.
[17] MINGES WOLS H A,UNDERHILL G H,KANSAS G S,et al. The role of bone marrow-derived stromal cells in the maintenance of plasma cell longevity[J]. J Immunol, 2002,169(8):4213-4221.
[18] YANG R,MASTERS A R,FORTNER K A,et al.IL-6 promotes the differentiation of a subset of naive CD8+ T cells into IL-21-producing B helper CD8+ T cells[J]. J Exp Med,2016,213(11):2281-2291.
[19] YU J,HECK S,YAZDANBAKHSH K.Prevention of red cell alloimmunization by CD25 regulatory T cells in mouse models[J]. Am J Hematol,2007,82(8):691-696.
[20] HENDRICKSON J E,DESMARETS M,DESHPANDE S S,et al.Recipient inflammation affects the frequency and magnitude of immunization to transfused red blood cells[J]. Transfusion,2006,46(9):1526-1536.
[21] KRIEG A M.CpG motifs in bacterial DNA and their immune effects[J]. Annu Rev Immunol,2002,20:709-760.
[22] WEST M A,WALLIN R P A,MATTHEWS S P,et al. Enhanced dendritic cell antigen capture via toll-like receptor-induced actin remodeling[J]. Science, 2004, 305(5687):1153-1157.
[23] CHENG P,ZHOU J,GABRILOVICH D.Regulation of dendritic cell differentiation and function by Notch and Wnt pathways[J]. Immunol Rev,2010,234(1):105-119.

黄芩苷预治疗对小鼠红细胞输注模型中IgG和IgM抑制作用的研究^*

Pretreatment with Baicalin Reduces the Production of IgG and IgM in a Mouse Model of Red Blood Cell Infusion

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

关于本刊

作者中心

在线期刊

访问统计

联系我们

[1]	刘卿, 王宗奎, 徐俊, 程露, 李长清, 杜晞, 马莉. 不同来源人血清白蛋白对血管内皮细胞生物学效应的影响研究^*[J]. 临床输血与检验, 2024, 26(5): 577-586.
[2]	朱心怡, 张成鑫, 王秋实, 李佳佳, 齐永, 向东, 赵俸涌. 常见红细胞添加剂成分对双花扁豆凝集素与A₁红细胞反应的影响^*[J]. 临床输血与检验, 2024, 26(5): 587-591.
[3]	王涛, 熊玉琪, 黄瑶, 王晓清. 单采血小板不同存储时间活化状态和微粒表达及个体差异分析[J]. 临床输血与检验, 2024, 26(5): 597-603.
[4]	苏晓敏, 张国权, 王锦, 徐华. 基于蛋白组学和代谢组学在血液存储中相关性分析[J]. 临床输血与检验, 2024, 26(5): 609-616.
[5]	谢如锋, 张景怡, 杨懿铭, 高跞, 蒋雪玉, 孙娟, 杨洁. 近红外低能量激光调节血小板活性氧水平对防止冷藏损伤的研究^*[J]. 临床输血与检验, 2024, 26(5): 617-623.
[6]	王静, 罗景艳, 张洁, 张涵奕, 张洪为, 黄远帅. 红细胞衍生的细胞外囊泡对红细胞储存损伤的初步研究[J]. 临床输血与检验, 2024, 26(5): 624-629.
[7]	郝梦玲, 汤龙海, 金一鸣, 肖琦, 方敏. 血浆制品中凝血因子Ⅷ含量及抽检结果的影响因素分析^*[J]. 临床输血与检验, 2024, 26(5): 630-637.
[8]	李雨薇, 黄霞, 周源, 刘颖, 王林, 邹彬彬, 刘胡敏, 马海莉, 许婷婷, 唐飞, 曹铭静, 侯玲华, 李玉军, 胡文佳, 冯惟萍, 刘妍妍, 段勇, 温涛, 李明霞, 邱艳. 2018—2022年我国18家省级血液中心献血者HCV检测结果分析^*[J]. 临床输血与检验, 2024, 26(5): 638-644.
[9]	乔艳辉, 郭伟鹏, 徐保红, 木耶赛尔·伊斯马依力. 新疆地区249例RhD变异型基因分型研究^*[J]. 临床输血与检验, 2024, 26(5): 645-650.
[10]	毛伟, 蒋玉林, 朱传福, 叶欣, 谢毓滨, 李晓丰, 吕蓉, 齐珺, 冯智慧, 苏湘辉, 徐筠娉, 汤龙海, 徐晶, 谭茜茜, 朱发明. 国内血小板基因库建设及应用的现状研究^*[J]. 临床输血与检验, 2024, 26(5): 656-660.
[11]	范成艳, 温玉洁, 廉雪, 张丹, 王洁, 敬媛媛, 王丽君, 李伟, 贾延军, 李冬妹. 免疫性血小板输注无效患者血清中血小板相关抗体的变化及其临床意义^*[J]. 临床输血与检验, 2024, 26(5): 661-666.
[12]	邓雪莲, 臧亮, 刘笑春, 孙鹏, 王颖颖, Daniel Candotti, 周俊. 基于HBV感染的确认探讨核酸检测反应性献血者的归队策略^*[J]. 临床输血与检验, 2024, 26(5): 667-674.
[13]	姜晓婕, 张景怡, 孟妍, 黄晨佳. 精准招募高校献血者工作的现状分析及对策探讨[J]. 临床输血与检验, 2024, 26(5): 680-682.
[14]	赵嘉璐, 范鑫秋, 曾一梅, 蔡晓红, 李佳明, 王学锋. TUBB1突变型骨髓增生异常综合症患者临床特征及血小板输注无效相关性分析[J]. 临床输血与检验, 2024, 26(5): 683-689.
[15]	陈淑銮, 郑壮荣. 基于作业成本法的血液产品成本核算的研究[J]. 临床输血与检验, 2024, 26(5): 690-695.